公开(公告)号：US09132190B2

公开(公告)日：2015-09-15

申请号：US14090778

申请日：2013-11-26

Applicant: AbbVie Inc.

Inventor： Lorenzo Benatuil ,  Erwin R. Boghaert ,  Jijie Gu ,  Maria Harris ,  Jonathan A. Hickson ,  Chung-Ming Hsieh ,  Yuliya Kutskova ,  Yingchun Li ,  Zhihong Liu ,  Susan Morgan-Lappe

IPC: A61K39/395 ,  C07K14/47 ,  C07K16/18 ,  C07K16/22 ,  A61K45/06 ,  C07K7/06 ,  C07K7/08

CPC classification number: C07K16/22 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K16/18 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.

Abstract translation: 描述了改进的DLL4结合蛋白，包括抗体，CDR-移植抗体，人抗体和DLL4结合片段，以高亲和力结合DLL4的蛋白质，以及中和DLL4活性的DLL4结合蛋白。 DLL4结合蛋白可用于治疗或预防癌症和肿瘤，特别是用于治疗或预防肿瘤血管生成和/或其它血管发生依赖性疾病，例如眼新生血管形成或以异常DLL4表达或活性为特征的血管发生非依赖性疾病，例如自身免疫 包括多发性硬化的疾病。

公开(公告)号：US20140348835A1

公开(公告)日：2014-11-27

申请号：US14301546

申请日：2014-06-11

Applicant: AbbVie Inc.

Inventor： Jijie Gu ,  Dominic J. Ambrosi ,  Susan E. Lappe ,  Yingchun Li ,  Jonathan A. Hickson ,  Deanna L. Haasch ,  Supriya Gupta ,  Ravi Chari ,  Camellia Zamiri ,  Louie Naumovski ,  Xianhua Cao

IPC: C07K16/46 ,  A61K31/4745 ,  A61K31/525 ,  C07K16/28 ,  A61K31/7068 ,  A61K31/337 ,  A61K31/513 ,  C07K16/22 ,  A61K39/395 ,  A61K31/495

CPC classification number: C07K16/468 ,  A61K31/337 ,  A61K31/4745 ,  A61K31/495 ,  A61K31/513 ,  A61K31/525 ,  A61K31/7068 ,  A61K39/395 ,  A61K39/3955 ,  A61K39/39591 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/22 ,  C07K16/28 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/64 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  A61K2300/00

Abstract: Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity.

Abstract translation: 本文公开了多价和多特异性结合蛋白，制备结合蛋白的方法及其在诊断，监测，抑制，预防和/或治疗癌症，肿瘤和/或其它血管发生依赖性疾病中的用途，所述疾病以异常DLL4为特征 和/或VEGF表达或活性。

公开(公告)号：US10195209B2

公开(公告)日：2019-02-05

申请号：US15363786

申请日：2016-11-29

Applicant: AbbVie Inc. ,  AbbVie Biotherapeutics Inc.

Inventor： Kurt C. Gish ,  Jonathan A. Hickson ,  Susan Elizabeth Morgan-Lappe ,  James W. Purcell

IPC: A61K38/07 ,  A61K31/5517 ,  C07K16/30 ,  A61K39/395 ,  A61K47/06 ,  C07K16/28 ,  A61K47/68

Abstract: The present disclosure provides antibodies, antibody binding fragments, and antibody drug conjugates that bind human LRRC15, their methods of making, and their uses to treat patients having cancer.

公开(公告)号：US20170151343A1

公开(公告)日：2017-06-01

申请号：US15363715

申请日：2016-11-29

Applicant: AbbVie Inc. ,  AbbVie Biotherapeutics Inc.

Inventor： Kurt C. GISH ,  Jonathan A. Hickson ,  Susan Elizabeth Morgan-Lappe ,  James W. Purcell

IPC: A61K47/48 ,  A61K38/07 ,  A61K31/5517 ,  C07K16/30

CPC classification number: A61K31/5517 ,  A61K38/07 ,  A61K39/3955 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6889 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/2818 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2317/77 ,  C07K2317/92 ,  A61K2300/00

Abstract: The present disclosure provides antibodies, antibody binding fragments, and antibody drug conjugates that bind human LRRC15, their methods of making, and their uses to treat patients having cancer.

公开(公告)号：US20160122439A1

公开(公告)日：2016-05-05

申请号：US14845511

申请日：2015-09-04

Applicant: AbbVie Inc.

Inventor： Jijie Gu ,  Dominic J. Ambrosi ,  Susan E. Lappe ,  Yingchun Li ,  Jonathan A. Hickson ,  Deanna L. Haasch ,  Supriya Gupta ,  Ravi Chari ,  Camellia Zamiri ,  Louie Naumovski ,  Xianhua Cao

IPC: C07K16/46 ,  C07K16/28 ,  C07K16/22

CPC classification number: C07K16/468 ,  A61K31/337 ,  A61K31/4745 ,  A61K31/495 ,  A61K31/513 ,  A61K31/525 ,  A61K31/7068 ,  A61K39/395 ,  A61K39/3955 ,  A61K39/39591 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/22 ,  C07K16/28 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/64 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  A61K2300/00

Abstract: Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity.

Abstract translation: 本文公开了多价和多特异性结合蛋白，制备结合蛋白的方法及其在诊断，监测，抑制，预防和/或治疗癌症，肿瘤和/或其它血管发生依赖性疾病中的用途，所述疾病以异常DLL4为特征 和/或VEGF表达或活性。

公开(公告)号：US09045551B2

公开(公告)日：2015-06-02

申请号：US14301546

申请日：2014-06-11

Applicant: AbbVie Inc.

Inventor： Jijie Gu ,  Dominic J. Ambrosi ,  Susan E. Lappe ,  Yingchun Li ,  Jonathan A. Hickson ,  Deanna L. Haasch ,  Supriya Gupta ,  Ravi Chari ,  Camellia Zamiri ,  Louie Naumovski ,  Xianhua Cao

IPC: C07K16/00 ,  C12P21/08 ,  A61K39/395 ,  A61K39/40 ,  C07K16/46 ,  A61K45/06 ,  C07K16/22 ,  A61K31/513 ,  A61K31/7068 ,  A61K31/337 ,  A61K31/4745 ,  A61K31/495 ,  A61K31/525 ,  C07K16/28 ,  C07K1/00 ,  A61K39/00

CPC classification number: C07K16/468 ,  A61K31/337 ,  A61K31/4745 ,  A61K31/495 ,  A61K31/513 ,  A61K31/525 ,  A61K31/7068 ,  A61K39/395 ,  A61K39/3955 ,  A61K39/39591 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/22 ,  C07K16/28 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/64 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  A61K2300/00

Abstract: Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases characterized by aberrant DLL4 and/or VEGF expression or activity.

Abstract translation: 本文公开了多价和多特异性结合蛋白，制备结合蛋白的方法及其在诊断，监测，抑制，预防和/或治疗癌症，肿瘤和/或其它血管发生依赖性疾病中的用途，其特征在于异常DLL4和 /或VEGF表达或活性。

公开(公告)号：US20140093521A1

公开(公告)日：2014-04-03

申请号：US14090778

申请日：2013-11-26

Applicant: ABBVIE INC.

Inventor： Lorenzo Benatuil ,  Erwin R. Boghaert ,  Jijie Gu ,  Maria Harris ,  Jonathan A. Hickson ,  Chung-Ming Hsieh ,  Yuliya Kutskova ,  Yingchun Li ,  Zhihong Liu ,  Susan Morgan-Lappe

IPC: A61K39/395 ,  A61K45/06 ,  C07K16/18 ,  C07K7/06 ,  C07K7/08

CPC classification number: C07K16/22 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K16/18 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.

Abstract translation: 描述了改进的DLL4结合蛋白，包括抗体，CDR-移植抗体，人抗体和DLL4结合片段，以高亲和力结合DLL4的蛋白质，以及中和DLL4活性的DLL4结合蛋白。 DLL4结合蛋白可用于治疗或预防癌症和肿瘤，特别是用于治疗或预防肿瘤血管生成和/或其它血管发生依赖性疾病，例如眼新生血管形成或以异常DLL4表达或活性为特征的血管发生非依赖性疾病，例如自身免疫 包括多发性硬化的疾病。